Patents Assigned to Oligos Etc. Inc.
-
Patent number: 7176191Abstract: The present invention provides protonated compounds having antimicrobial activity. The invention also provides antimicrobial compositions comprising protonated compounds of the invention. The protonated compounds of the invention provide efficacious antimicrobial activity against resistant strains of bacteria and opportunistic fungi.Type: GrantFiled: September 8, 2004Date of Patent: February 13, 2007Assignee: Oligos Etc. Inc.Inventors: Roderic M. K. Dale, Steven L. Gatton, Amy Arrow, Terry Thompson
-
Patent number: 6958239Abstract: This invention relates to antisense oligonucleotides that target mRNAs in cells as substrates for the cellular enzyme RNase H and thereby cause specific degradation of the targeted mRNA. The oligonucleotides have three components: an RNase H activating region, a complementary region and 3? and 5? ends. The invention optimizes each of the components to resist intracellular nucleases, to increase hybridization to target mRNA, to specifically inactivate target mRNA in cells, and to decrease cytotoxicity.Type: GrantFiled: December 15, 1998Date of Patent: October 25, 2005Assignee: Oligos Etc Inc.Inventors: Amy Arrow, Roderic M. K. Dale, Tod Mitchell Woolf
-
Patent number: 6844151Abstract: The present invention provides methods for producing arrays having associated modified nucleic acid structures, e.g. acid stable and/or end-blocked nucleic acids such as 2?-O—R oligonucleotides. In one embodiment, arrays produced using the methods of the invention exhibit an increased binding affinity with complementary nucleic acids, and in particular with complementary RNA. In another embodiment, the associated nucleic acids of the array produced using the methods of the invention exhibit substantial acid resistance, allowing the arrays to be treated with low pH solutions. In another embodiment, the modified associated nucleic acids of the array produced using the methods of the invention exhibit substantial resistance to nuclease degradation.Type: GrantFiled: September 29, 1999Date of Patent: January 18, 2005Assignee: Oligos Etc. Inc.Inventor: Roderic M. K. Dale
-
Publication number: 20040121352Abstract: The present invention provides arrays having associated modified oligonucleotides that selectively bind to DNA or RNA, methods of making such arrays, assays for using such arrays, and the like. In one embodiment, the arrays of the invention exhibit an increased binding affinity with complementary nucleic acids, and in particular with complementary RNA. In another embodiment, the associated nucleic acids of the array of the invention exhibit substantial acid resistance, allowing the arrays to be treated with low pH solutions. In another embodiment, the modified associated nucleic acids of the array of the invention exhibit substantial resistance to nuclease degradation.Type: ApplicationFiled: April 17, 2003Publication date: June 24, 2004Applicant: Oligos Etc. Inc.Inventor: Roderic M.K. Dale
-
Patent number: 6627215Abstract: The present invention provides devices and compositions for the management of infection of topical lesions, each of the devices and compositions containing protonated/acidified nucleic acids either on its surface, or integrated into the device. These modified nucleic acids are effective as bactericidal and/or bacteriostatic agents without regard to the class of bacteria, so are especially useful when diagnosis is difficult or when multiple infectious organisms are present. The antibiotic activity of nucleic acids of the invention is not dependent on either the specific sequence of the nucleic acid or the length of the nucleic acid molecule. The nucleic acids used in the invention are protonated/acidified to give a pH when dissolved in water of less than pH 7 to about 1, more preferably less than pH 4.5 to about 1, and even more preferably less than pH 2 to about 1.Type: GrantFiled: March 31, 1999Date of Patent: September 30, 2003Assignee: Oligos Etc. Inc.Inventors: Roderic M. K. Dale, Steven L. Gatton, Amy Arrow
-
Patent number: 6562569Abstract: The present invention provides arrays having associated modified oligonucleotides that selectively bind to DNA or RNA, methods of making such arrays, assays for using such arrays, and the like. In one embodiment, the arrays of the invention exhibit an increased binding affinity with complementary nucleic acids, and in particular with complementary RNA. In another embodiment, the associated nucleic acids of the array of the invention exhibit substantial acid resistance, allowing the arrays to be treated with low pH solutions. In another embodiment, the modified associated nucleic acids of the array of the invention exhibit substantial resistance to nuclease degradation.Type: GrantFiled: March 13, 2000Date of Patent: May 13, 2003Assignee: Oligos Etc. Inc.Inventor: Roderic M. K. Dale
-
Publication number: 20030045490Abstract: This patent describes the invention of a series of novel therapeutic oligonucleotides targeted at inhibiting expression of genes coding for Phosphodiesterase 4. They are useful as analytical tools in the study of individual PDE isoforms and in the therapeutic treatment of depression, thrombosis, cystic fibrosis, gastric lesions, pulmonary hypertension, glaucoma, multiple sclerosis, atopic dermatitis, asthma and other allergic disorders as well as other illnesses in which an increase of cyclic AMP or a decrease in phosphodiesterase levels is useful.Type: ApplicationFiled: February 19, 2002Publication date: March 6, 2003Applicant: Oligos Etc. Inc.Inventors: Roderic M.K. Dale, Amy Arrow, Terry Thompson
-
Patent number: 6440723Abstract: Binding units such as avidin or biotin are placed on tightly defined areas of a solid planar support surface. Polymer sequences such as oligonucleotides are synthesized with a complementary binding unit attached, preferably via a linker moiety. The polymer/linker/binding units are then placed on the binding units on the support surface and an array is formed.Type: GrantFiled: March 17, 2000Date of Patent: August 27, 2002Assignee: Oligos Etc. Inc.Inventor: Roderic M. K. Dale
-
Patent number: 6211349Abstract: The novel discovery that protonated nucleic acids inhibit bacterial growth is reported and methods for the preparation and therapeutic use of nuclease resistant and acid resistant protonated/acidified nucleic acids for administration to animals including man, to treat or prevent a bacterial infection are described.Type: GrantFiled: December 30, 1998Date of Patent: April 3, 2001Assignee: Oligos Etc., Inc.Inventors: Roderic M. K. Dale, Amy Arrow, Steven L. Gatton, Terry Thompson
-
Patent number: 6211162Abstract: The present invention provides a method of treating bacterial respiratory infections by pulmonary administration of protonated/acidified nucleic acids. These modified nucleic acids are effective as bactericidal and/or bacteriostatic agents without regard to the class of bacteria, so are especially useful when diagnosis is difficult or when multiple infectious organisms are present. The antibiotic activity of nucleic acids of the invention is not dependent on either the specific sequence of the nucleic acid or the length of the nucleic acid molecule.Type: GrantFiled: March 31, 1999Date of Patent: April 3, 2001Assignee: Oligos Etc. Inc.Inventors: Roderic M. K. Dale, Steven L. Gatton, Amy Arrow
-
Patent number: 6087112Abstract: The present invention provides arrays having associated modified oligonucleotides, e.g., 2'-O-R oligonucleotides, methods of making such arrays, assays for using such arrays, and kits containing such arrays. In one embodiment, the arrays of the invention exhibit an increased binding affinity with complementary nucleic acids, and in particular with complementary RNA. In another embodiment, the associated nucleic acids of the array of the invention exhibit substantial acid resistance, allowing the arrays to be treated with low pH solutions. In another embodiment, the modified associated nucleic acids of the array of the invention exhibit substantial resistance to nuclease degradation.Type: GrantFiled: September 29, 1999Date of Patent: July 11, 2000Assignee: Oligos Etc. Inc.Inventor: Roderic M. K. Dale
-
Patent number: 6015886Abstract: This invention relates to synthetic oligonucleotides that are useful for antisense based therapeutic applications. The synthetic oligonucleotides of this invention have modifications in the sugar phosphate backbone for improved antisense properties.Type: GrantFiled: February 5, 1997Date of Patent: January 18, 2000Assignees: ChemGenes Corporation, Oligos Etc., Inc.Inventors: Roderic M. K. Dale, Amy Arrow, Suresh C. Srivastava, Syed K. Raza
-
Patent number: 5989912Abstract: This invention relates to antisense oligonucleotides that target mRNAs in cells as substrates for the cellular enzyme RNase H and thereby cause specific degradation of the targeted mRNA. The oligonucleotides have three components: a RNase H activating region, a complementarity region and 3' and 5' ends. The invention optimizes each of the components to resist intracellular nucleases, to increase hybridization to target mRNA, to specifically inactivate target mRNA in cells, and to decrease cytotoxicity.Type: GrantFiled: December 15, 1998Date of Patent: November 23, 1999Assignees: Oligos Etc. Inc., Tod Mitchell WoolfInventors: Amy Arrow, Roderic M. K. Dale, Tod Mitchell Woolf
-
Patent number: 5849902Abstract: This invention relates to antisense oligonucleotides that target mRNAs in cells as substrates for the cellular enzyme RNase H and thereby cause specific degradation of the targeted mRNA. The oligonucleotides have three components: a RNase H activating region, a complementarity region and 3' and 5' ends. The invention optimizes each of the components to resist intracellular nucleases, to increase hybridization to target mRNA, to specifically inactivate target mRNA in cells, and to decrease cytotoxicity.Type: GrantFiled: November 21, 1996Date of Patent: December 15, 1998Assignees: Oligos Etc. Inc., Tod Mitchell WoolfInventors: Amy Arrow, Roderic M.K. Dale, Tod Mitchell Woolf